Form 4: Heron Therapeutics CFO Converts RSUs to Common Stock

Heron Therapeutics' EVP and CFO, Ira Duarte, converted 11,695 restricted stock units into common stock on January 31, 2026.

Summary

• Ira Duarte, Executive Vice President and Chief Financial Officer of HERON THERAPEUTICS, INC. (HRTX), acquired 11,695 shares of common stock.
• This acquisition resulted from the exercise of 11,695 restricted stock units (RSUs).
• Following the transaction, Ira Duarte directly beneficially owns 195,356 shares of common stock.
• The transaction occurred on January 31, 2026.
• Each restricted stock unit represents a contingent right to receive one share of common stock.
• The restricted stock units vest in 16 equal installments, beginning one quarter after the grant date of January 31, 2025.
• After the conversion, Ira Duarte directly beneficially owns 140,332 restricted stock units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it's a routine compensation matter, an executive increasing their direct stock ownership can be seen as a minor positive signal of alignment with shareholder interests.

Positives

• The conversion of restricted stock units into common stock increases the executive's direct ownership in the company, aligning their interests with shareholders.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

StockSavvy.ai notes that the conversion of restricted stock units (RSUs) into common stock is a routine event in executive compensation, reflecting the vesting of previously granted equity awards. This type of transaction is common across various industries as a mechanism to incentivize and retain key management personnel.

Stakeholder Impact

• Shareholders: A minor increase in the number of outstanding shares due to the conversion, and a potential positive signal from executive stock ownership.
• Employees: No direct impact mentioned.

Next Steps

• Continued vesting of the remaining 140,332 restricted stock units held by Ira Duarte according to the established schedule.

Key Dates

Recommendation

This Form 4 reports a routine conversion of restricted stock units by an executive, which does not provide new fundamental information to alter an investment thesis. Such transactions are part of standard compensation practices and typically do not warrant a change in investment recommendation.

Keywords

Heron Therapeutics, HRTX, Insider Transaction, Form 4, Restricted Stock Units, RSU Conversion, Executive Compensation, Ira Duarte